Sarah J. Nelson1, 2, John Kurhanewicz3, Daniel B. Vigneron, Peder Larson, Andrea Harzstarck, Marcus Ferrone, Mark van Criekinge, Jose Chang, Robert Bok, Ilwoo Park, Galen Reed, Lucas Carvajal, Jason Crane, Jan Henrik Ardenkjaer-Larsen4, Albert Chen5, Ralph Hurd6, Liv-Ingrid Odegardstuen7, James Tropp6
1Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States; 2Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States; 3University of California, San Francisco, United States; 4General Electric Healthcare, Denmark; 5General Electric Healthcare, Toronto, Canada; 6General Electric Healthcare, Fremont, CA, USA; 7General Electric Healthcare, Oslo, Norway
The first clinical trial using C-13 MR metabolic imaging has been successfully performed in patients with biopsy proven prostate cancer. In this dose escalation study 31 patients received an injection of 250mM hyperpolarized C-13 pyruvate, followed by metabolic imaging at 3T. Dynamic data showed arrival of C-13 pyruvate approximately 20 seconds after injection and demonstrated that the T1 was long enough to detect uptake and conversion to lactate for 60+ seconds. There were no dose limiting toxicities observed. The highest dose of 0.43mL/Kg gave the best lactate SNR and contrast in lactate/pyruvate for tumor relative to normal prostate.